Is Indrapr.Medical overvalued or undervalued?

As of 7 October 2025, Indrapr.Medical's valuation grade has moved from attractive to fair, indicating a shift in market perception. The company is currently fairly valued. Key ratios include a PE ratio of 31.37, an EV to EBITDA of 19.73, and a PEG ratio of 1.47, which suggest that while the company is performing well, its valuation is more aligned with its earnings growth expectations rather than indicating significant undervaluation.
In comparison to its peers, Indrapr.Medical's valuation appears reasonable against Max Healthcare's very expensive PE of 90.89 and Apollo Hospitals' attractive PE of 70.33. The company's strong ROCE of 66.94% and ROE of 28.10% further highlight its operational efficiency, but the current price of 573.80 reflects a market that has already priced in much of this performance. Notably, Indrapr.Medical has outperformed the Sensex significantly over the past year, with a return of 44.88% compared to the Sensex's 1.08%, reinforcing the narrative of its strong market position despite its fair valuation status.